Repros Therapeutics Inc. Reports That Patients Exposed to Proellex For Up To Six Months Demonstrated A Benign Endometrium Based On Biopsy

THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today released the endometrial biopsy findings from its three and six month studies of Proellex™ in the treatment of uterine fibroids and endometriosis respectively. The clinical study results of efficacy and top-line safety were reported in April and June 2007 and in both instances unequivocal efficacy was demonstrated in the treatment of both conditions with reduction of pain associated with endometriosis and reduction of bleeding in uterine fibroids.